Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Piper Jaffray Cuts Price Target on Orexigen Therapeutics (OREX) to $5 Following 4Q Results
February 29, 2016 8:13 AM ESTPiper Jaffray maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $5.00 (from $11.00), following the company's 4Q earnings report. US Contrave royalties of $2.6M, helped OREX end 2015 with $214M of cash, sufficient through profitability based on growing revenues. Orexigen reported 4Q15 revenues of $4.9M, including $2.6M in Contrave... More
UPDATE: RBC Capital Downgrades Orexigen Therapeutics (OREX) to Sector Perform
February 29, 2016 6:52 AM EST(Updated - February 29, 2016 8:24 AM EST)
RBC Capital downgraded Orexigen Therapeutics (NASDAQ: OREX) from Outperform to Sector Perform with a price target of $1.00 (from $5.00). Analyst Simos Simeonidis sees a tougher road for Contrave/ Mysimba.
"Despite the already significant decline in OREX shares, we are downgrading to Sector Perform on what we view as a bleak outlook for both the US... More
